CEO's Health Journey Inspires Platform Aiding Over 90,000 in Weight Loss

CEO's Health Journey Inspires Platform Aiding Over 90,000 in Weight Loss

In less than two years, OrderlyMeds, a bootstrapped startup based in Atlanta, has attracted over 90,000 customers seeking more effective and personalized weight loss support.

OrderlyMeds, a telemedicine startup, originated from Founder and CEO Chris Spears' personal experience using GLP-1s, a class of medications that includes well-known weight loss treatments such as Ozempic and Wegovy.

Spears is among a growing number of Americans experimenting with GLP-1s. Research indicates that one in eight Americans has experimented with GLP-1 medication; however, access and support remain problematic.

OrderlyMeds aims to address this issue. The platform represents a move toward personalized health, recognizing that weight loss involves ongoing support, education, and tailored care, rather than just medication.

Spears estimates he has launched 39 ventures since high school. Arke, a B2B marketing technology consulting firm based in Atlanta, was his most successful venture before OrderlyMeds. He led it for 17 years before selling it in 2021.

Shortly after, he entered "retirement mode." However, his health declined, leading to an ICU stay in October 2022. During his recovery, his primary care physician prescribed a GLP-1. However, it was not covered by insurance and was unavailable at his pharmacy.

Consequently, like many others, he used a telemedicine company that sold GLP-1 medications online.

Spears found the medication to be "life-changing", but the user experience on the telemedicine platform was lacking. He felt it lacked the support services needed to help patients succeed. Health tracking apps like Shotlee can help monitor progress and adherence to medication regimens.

This is where Spears identified an opportunity.

Today, OrderlyMeds provides GLP-1 users with a more personalized treatment experience. Following a virtual consultation and weight loss evaluation, OrderlyMeds' third-party medical teams can ship GLP-1 medications directly to the customer. The platform then offers ongoing community support to assist with dosage adjustments, answer questions, and facilitate the achievement of individual health objectives.

Spears established the company in October 2023, bringing in several individuals from his previous ventures. After a rapid build-out, OrderlyMeds launched in January 2024, aiming to capitalize on New Year's resolution momentum.

They acquired a total of 17 initial customers.

However, this slow start was short-lived. By the end of the first year, OrderlyMeds had assisted 24,000 individuals with their weight loss journeys. By the end of 2025, that number had increased to over 90,000.

This has resulted in over 2 million pounds lost.

Key Factors in Success

The team did not prioritize paid media during their first year.

Spears stated that they concentrated on their customer experience. Initially, 25% of new customers came from existing customer referrals, and another 25% came from organic search.

The remaining 50% discovered OrderlyMeds through social media influencers who shared their personal weight loss experiences without being paid.

Spears noted that this still generates 30 to 40% of their customers each month.

OrderlyMeds began as a direct-to-consumer venture. However, the company is expanding into the B2B sector by selling to benefit brokers, corporate partners, and pharmacies struggling to meet GLP-1 demand. It is also developing additional brands to extend its telemedicine platform into other healthcare areas, diversifying revenue across a broader healthcare spectrum, according to Spears.

As of November 2025, the bootstrapped startup had over 160 W2 employees and around 200 1099 contractors.

Spears also stated that they grew from $1 to $100 million ARR in 11 months, from May 2024 to March 2025.